Yunnan Zhongke Longjin Biotechnology

Yunnan Zhongke Longjin Biotechnology is a Chinese biopharmaceutical company specializing in the development and production of genetic engineering drugs. A joint venture involving Kunming Longjin Pharmaceutical and the Kunming Institute of Zoology (Chinese Academy of Sciences), the company focuses on recombinant human basic fibroblast growth factor (rhbFGF) products. Its primary offerings include topical solutions and lyophilized powders used for wound healing, burn treatment, and tissue repair. The company operates GMP-certified manufacturing facilities and leverages advanced protein expression platforms to serve the clinical and aesthetic medicine markets.